Archive for the ‘QCOR’ Category

Mallinckrodt Gets Money-Making Acthar Gel by Acquiring Questcor

Monday, April 7th, 2014

Mallinckrodt will gain Questcor’s lucrative drug Acthar Gel, which treats autoimmune and inflammatory diseases. Sales of the drug jumped about 50% year-over-year in 2013.

Barrow Fund Sees Safe Returns in Smith & Wesson, Raytheon

Thursday, February 20th, 2014

Companies in the Barrow All-Cap Core Fund are merger targets four times more than the market at large because the fund’s managers take a private equity approach to stock-picking.

Cramer’s ‘Mad Money’ Recap: Best-Performing Stocks

Thursday, August 29th, 2013

Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

NEW YORK (TheStreet) — It’s time to start circling back to the best-performing stocks, Jim Cramer told his “Mad Money” TV show viewers Wednesday. Cramer said that when the bad news from Syria finally begins to subside, the stocks with the best earnings will be the first to rebound.

It may not be time just yet, but Cramer said he’d have money at the ready to buy stocks including TJX Stores and Urban Outfitters , two of the best-performing retail stocks of this quarter. He was also bullish on Celgene and Gilead Sciences among the biotech group. …

Click to view a price quote on TJX.

Click to research the Retail industry.


SodaStream Pops, Fed Talks

Wednesday, July 31st, 2013

SodaStream bubbles higher on strong quarterly results. Buffalo Wild Wings and Questcor are also higher ahead of the Fed’s announcement.

The 5 Dumbest Things on Wall Street This Week: Sept. 28

Friday, September 28th, 2012

5. Blyth’s Catch-22

If only Blyth could somehow combine its candle-making and weight-loss businesses then maybe its shareholders will stop getting burned at both ends.

Blyth stockholders were less than blithe (the happy kind of blithe) this past week after seeing their shares plunge more than 40% to $25 as a result of a Moody’s downgrade and the company’s subsequent decision to abandon the IPO of its rapidly growing nutritional products division ViSalus. The ratings agency chopped its view of Blyth to “negative” from “stable” late last Thursday, citing concerns about the company’s financial wherewithal once it completed its plan to spin off ViSalus. Moody’s decision put so much selling pressure on the stock that Blyth ultimately announced on Wednesday it would cancel the offering and keep the division in house.

Click to view a price quote on BTH.

Click to research the Consumer Non-Durables industry.